The 36-month beta value for CYCC is also noteworthy at 0.62. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CYCC is 205.34M, and at present, short sellers hold a 0.03% of that float. The average trading volume of CYCC on April 08, 2025 was 468.75K shares.
CYCC) stock’s latest price update
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)’s stock price has gone decline by -12.15 in comparison to its previous close of 0.21, however, the company has experienced a -32.66% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-04-02 that BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update.
CYCC’s Market Performance
CYCC’s stock has fallen by -32.66% in the past week, with a monthly drop of -40.88% and a quarterly drop of -59.13%. The volatility ratio for the week is 14.78% while the volatility levels for the last 30 days are 8.70% for Cyclacel Pharmaceuticals Inc The simple moving average for the past 20 days is -34.12% for CYCC’s stock, with a -75.95% simple moving average for the past 200 days.
Analysts’ Opinion of CYCC
Many brokerage firms have already submitted their reports for CYCC stocks, with Oppenheimer repeating the rating for CYCC by listing it as a “Outperform.” The predicted price for CYCC in the upcoming period, according to Oppenheimer is $17 based on the research report published on July 18, 2022 of the previous year 2022.
ROTH Capital, on the other hand, stated in their research note that they expect to see CYCC reach a price target of $24. The rating they have provided for CYCC stocks is “Buy” according to the report published on April 27th, 2020.
CYCC Trading at -40.60% from the 50-Day Moving Average
After a stumble in the market that brought CYCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.30% of loss for the given period.
Volatility was left at 8.70%, however, over the last 30 days, the volatility rate increased by 14.78%, as shares sank -38.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.33% lower at present.
During the last 5 trading sessions, CYCC fell by -32.66%, which changed the moving average for the period of 200-days by -87.47% in comparison to the 20-day moving average, which settled at $0.2854. In addition, Cyclacel Pharmaceuticals Inc saw -50.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYCC starting from Lazar David E., who sale 194,628,820 shares at the price of $0.03 back on Feb 26 ’25. After this action, Lazar David E. now owns 0 shares of Cyclacel Pharmaceuticals Inc, valued at $5,507,996 using the latest closing price.
Stock Fundamentals for CYCC
Current profitability levels for the company are sitting at:
- -254.88 for the present operating margin
- 0.84 for the gross margin
The net margin for Cyclacel Pharmaceuticals Inc stands at -155.08. The total capital return value is set at 19.44. Equity return is now at value -807.39, with -173.81 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 486.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.59.
Conclusion
In summary, Cyclacel Pharmaceuticals Inc (CYCC) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
